Cargando…

The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum

Detalles Bibliográficos
Autores principales:	Kleynhans, Janke, Duatti, Adriano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448838/ https://www.ncbi.nlm.nih.gov/pubmed/36068452 http://dx.doi.org/10.1186/s41181-022-00175-y

Ejemplares similares

A suitable time point for quantifying the radiochemical purity of (225)Ac-labeled radiopharmaceuticals
por: Kelly, James M., et al.
Publicado: (2021)

Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry
por: Kleynhans, Janke, et al.
Publicado: (2023)

Influence of Storage Temperature on Radiochemical Purity of (99m)Tc-Radiopharmaceuticals
por: Uccelli, Licia, et al.
Publicado: (2018)

The use of HEPES-buffer in the production of gallium-68 radiopharmaceuticals – time to reconsider strict pharmacopoeial limits?
por: le Roux, Jannie, et al.
Publicado: (2021)

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
por: Larenkov, Anton, et al.
Publicado: (2019)

Synthesis and Stability of Actinium-225 Endohedral Fullerenes, (225)Ac@C(60)
por: Mwakisege, Jofa Gideon, et al.
Publicado: (2020)

Supply and Clinical Application of Actinium-225 and Bismuth-213
por: Morgenstern, Alfred, et al.
Publicado: (2020)

Quality control on radiochemical purity in Technetium-99m radiopharmaceuticals labelling: three years of experience on 2280 procedures
por: Maioli, Claudio, et al.
Publicado: (2017)

Radiolysis-Associated Decrease in Radiochemical Purity of (177)Lu-Radiopharmaceuticals and Comparison of the Effectiveness of Selected Quenchers against This Process
por: Larenkov, Anton, et al.
Publicado: (2023)

An Overview of Targeted Alpha Therapy with (225)Actinium and (213)Bismuth
por: Morgenstern, Alfred, et al.
Publicado: (2018)

An alternative methodology for the determination of the radiochemical purity of (11)C-methionine
por: Giglio, Javier, et al.
Publicado: (2018)

Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies
por: Abou, Diane S., et al.
Publicado: (2022)

Recent Innovations and Nano-Delivery of Actinium-225: A Narrative Review
por: Mdanda, Sipho, et al.
Publicado: (2023)

Alpha Therapy with (225)Actinium Labeled Prostate Specific Membrane Antigen: Reporting New Photopeak of 78 Kilo-electron Volts for Better Image Statistics
por: Rasheed, Rashid, et al.
Publicado: (2019)

The DOTA macrocyclic cavity in metallic radiopharmaceuticals: Mythology or reality?
por: Duatti, Adriano
Publicado: (2023)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Validation of the HPLC Analytical Method for the Determination of Chemical and Radiochemical Purity of Ga-68-DOTATATE
por: Sammartano, Antonino, et al.
Publicado: (2023)

Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals
por: de Blois, Erik, et al.
Publicado: (2019)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Targeted Auger electron-emitter therapy: Radiochemical approaches for thallium-201 radiopharmaceuticals
por: Rigby, Alex, et al.
Publicado: (2021)

Evaluation of Actinium-225 Labeled Minigastrin Analogue [(225)Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy
por: Qin, Yun, et al.
Publicado: (2020)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225
por: Salvanou, Evangelia-Alexandra, et al.
Publicado: (2020)

Technetium Complexes and Radiopharmaceuticals with Scorpionate Ligands
por: Martini, Petra, et al.
Publicado: (2018)

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists
por: Shi, Mengqi, et al.
Publicado: (2022)

Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227
por: Anderson, Peter M., et al.
Publicado: (2022)

Modulating the pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin
por: Reissig, Falco, et al.
Publicado: (2022)

Optimization of Cation Exchange for the Separation of Actinium-225 from Radioactive Thorium, Radium-223 and Other Metals
por: Fitzsimmons, Jonathan, et al.
Publicado: (2019)

Development of (225)Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
por: Robertson, Andrew Kyle Henderson, et al.
Publicado: (2018)

Development and Validation of Analytical Methods for Radiochemical Purity of (177)Lu-PSMA-1
por: Orhon, Pauline, et al.
Publicado: (2022)

Daratumumab-(225)Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors
por: Dawicki, Wojciech, et al.
Publicado: (2019)

A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
por: Bolcaen, Julie, et al.
Publicado: (2021)

An investigation of aspects of radiochemical purity of (99m)Tc-labelled human serum albumin nanocolloid
por: Cusnir, Ruslan, et al.
Publicado: (2021)

Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study
por: Reissig, Falco, et al.
Publicado: (2021)

The subspecialty conundrum
por: Krishnamurthy, Rajesh
Publicado: (2010)

Influence of DOTA Chelators on Radiochemical Purity and Biodistribution of (177)Lu- and (90)Y-Rituximab in Xenografted Mice
por: Karczmarczyk, Urszula, et al.
Publicado: (2018)

(225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
por: Aras, Omer, et al.
Publicado: (2021)

Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis
por: Parida, Girish Kumar, et al.
Publicado: (2023)

An Experimental Generator for Production of High-Purity (212)Pb for Use in Radiopharmaceuticals
por: Li, Ruth Gong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2bsffi860fq2b7vuds6le6mlv4